Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832 Phase 2 TERMINATED Results posted

The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.

Details

Lead sponsor	Stanford University
Phase	Phase 2
Status	TERMINATED
Enrolment	50
Start date	2007-01
Completion	2017-03-30

Conditions

• Lymphoma, Non-Hodgkin

Interventions

• Cyclophosphamide
• BCNU
• Etoposide
• Filgrastim
• Antithymocyte globulin
• Cyclosporine
• Mycophenolate mofetil
• Rituximab
• Autologous hematopoietic stem cell transplantation (auto-HSCT)
• Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Primary outcomes

• Event-free Survival (EFS) — 3 years
  Event-free survival (EFS) as determined for participants who receive both planned transplants, for a minimum of 3 years. Events are defined as "disease progression/relapse" and "death of all causes".

Countries

United States